WO1999004824A1 - Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs - Google Patents

Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs Download PDF

Info

Publication number
WO1999004824A1
WO1999004824A1 PCT/US1998/015457 US9815457W WO9904824A1 WO 1999004824 A1 WO1999004824 A1 WO 1999004824A1 US 9815457 W US9815457 W US 9815457W WO 9904824 A1 WO9904824 A1 WO 9904824A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
polymeric
serotonin
construct
poly
Prior art date
Application number
PCT/US1998/015457
Other languages
English (en)
Inventor
John R. Lau
W. Blair Geho
Original Assignee
Sdg, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sdg, Inc. filed Critical Sdg, Inc.
Priority to CA002297025A priority Critical patent/CA2297025A1/fr
Priority to EP98937127A priority patent/EP0999855A1/fr
Priority to JP2000503875A priority patent/JP2001510811A/ja
Priority to AU85912/98A priority patent/AU8591298A/en
Publication of WO1999004824A1 publication Critical patent/WO1999004824A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une construction polymère permettant d'administrer un agent biologiquement actif à un mammifère, laquelle construction comprend une première matrice polymère, un agent biologiquement actif contenu dans la matrice polymère et un second polymère chimiquement lié à l'agent biologiquement actif, ledit second polymère comprenant un copolymère d'acides aminés, ledit second polymère étant présent selon une dose efficace, pour réduire la fuite de l'agent actif de la construction polymère avant l'administration à l'emplacement voulu.
PCT/US1998/015457 1997-07-25 1998-07-24 Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs WO1999004824A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002297025A CA2297025A1 (fr) 1997-07-25 1998-07-24 Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs
EP98937127A EP0999855A1 (fr) 1997-07-25 1998-07-24 Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs
JP2000503875A JP2001510811A (ja) 1997-07-25 1998-07-24 生物活性物質を標的に供給するための重合体ベースの薬剤組成物
AU85912/98A AU8591298A (en) 1997-07-25 1998-07-24 Polymer based pharmaceutical compositions for targeted delivery of biologically active agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5372997P 1997-07-25 1997-07-25
US60/053,729 1997-07-25

Publications (1)

Publication Number Publication Date
WO1999004824A1 true WO1999004824A1 (fr) 1999-02-04

Family

ID=21986168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015457 WO1999004824A1 (fr) 1997-07-25 1998-07-24 Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs

Country Status (6)

Country Link
EP (1) EP0999855A1 (fr)
JP (1) JP2001510811A (fr)
CN (1) CN1264310A (fr)
AU (1) AU8591298A (fr)
CA (1) CA2297025A1 (fr)
WO (1) WO1999004824A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588754B2 (en) 2005-05-10 2009-09-15 Nitto Denko Corporation Biodegradable polyacetals and methods
US7674452B2 (en) 2005-03-16 2010-03-09 Nitto Denko Corporation Polymer coating of cells
US8383091B2 (en) 2003-09-29 2013-02-26 Nitto Denko Corporation Biodegradable polyacetals for in vivo polynucleotide delivery
US10611857B2 (en) 2017-08-02 2020-04-07 Exxonmobil Chemical Patents Inc. Bisphenolate transition metal complexes, production and use thereof
US11634512B2 (en) 2017-01-27 2023-04-25 Cornell University Zwitterionically modified polymers and hydrogels

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086627A1 (fr) * 1982-02-12 1983-08-24 Unitika Ltd. Produit anti-cancéreux
WO1990005522A1 (fr) * 1988-11-17 1990-05-31 Per Prisell Preparation pharmaceutique
EP0467389A2 (fr) * 1990-07-19 1992-01-22 University Of Kentucky Research Foundation Système de délivrance de drogue à l'aide de l'interaction entre une protéine ou polypeptide et un polymère biodégradable hydrophobe
WO1994011015A1 (fr) * 1992-11-12 1994-05-26 Molecular Dynamics, Inc. Porteurs lipophiles a base de peptides destines a l'administration ciblee de medicaments selon un concept rationnel de fixation des medicaments
WO1995000547A1 (fr) * 1993-06-22 1995-01-05 E.I. Du Pont De Nemours And Company Composition antimicrobienne comprenant un polymere et un peptide formant des helices amphiphiles du type magainine
WO1996004001A1 (fr) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Complexes biomoleculaires diriges

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086627A1 (fr) * 1982-02-12 1983-08-24 Unitika Ltd. Produit anti-cancéreux
WO1990005522A1 (fr) * 1988-11-17 1990-05-31 Per Prisell Preparation pharmaceutique
EP0467389A2 (fr) * 1990-07-19 1992-01-22 University Of Kentucky Research Foundation Système de délivrance de drogue à l'aide de l'interaction entre une protéine ou polypeptide et un polymère biodégradable hydrophobe
WO1994011015A1 (fr) * 1992-11-12 1994-05-26 Molecular Dynamics, Inc. Porteurs lipophiles a base de peptides destines a l'administration ciblee de medicaments selon un concept rationnel de fixation des medicaments
WO1995000547A1 (fr) * 1993-06-22 1995-01-05 E.I. Du Pont De Nemours And Company Composition antimicrobienne comprenant un polymere et un peptide formant des helices amphiphiles du type magainine
WO1996004001A1 (fr) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Complexes biomoleculaires diriges

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383091B2 (en) 2003-09-29 2013-02-26 Nitto Denko Corporation Biodegradable polyacetals for in vivo polynucleotide delivery
US7674452B2 (en) 2005-03-16 2010-03-09 Nitto Denko Corporation Polymer coating of cells
US8216558B2 (en) 2005-03-16 2012-07-10 Nitto Denko Corporation Polymer coating of cells
US7588754B2 (en) 2005-05-10 2009-09-15 Nitto Denko Corporation Biodegradable polyacetals and methods
US11634512B2 (en) 2017-01-27 2023-04-25 Cornell University Zwitterionically modified polymers and hydrogels
US10611857B2 (en) 2017-08-02 2020-04-07 Exxonmobil Chemical Patents Inc. Bisphenolate transition metal complexes, production and use thereof

Also Published As

Publication number Publication date
AU8591298A (en) 1999-02-16
JP2001510811A (ja) 2001-08-07
CN1264310A (zh) 2000-08-23
EP0999855A1 (fr) 2000-05-17
CA2297025A1 (fr) 1999-02-04

Similar Documents

Publication Publication Date Title
US6063400A (en) Targeted liposomal constructs for diagnostic and therapeutic uses
EP0545913B1 (fr) Systèmes de délivrance pour agents pharmacologiques
US9526705B2 (en) Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
Kast et al. Thiolated polymers—thiomers: development and in vitro evaluation of chitosan–thioglycolic acid conjugates
Guggi et al. Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin
US20120208848A1 (en) Gacyclidine formulations
US20020176841A1 (en) Pharmaceutical formulations for sustained release
Hosny Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin
BRPI0707044B1 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
KR20060073538A (ko) 남용 방지성 암페타민 화합물
WO2009100441A2 (fr) Formulations retard depot formulations
EP0999855A1 (fr) Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs
JPH0733682A (ja) 新規複合体、それを担体として利用する徐放性製剤
CN113616620B (zh) 安罗替尼白蛋白纳米颗粒及其制备方法和用途、及包含其的制剂
WO1997034580A1 (fr) Composition pour suppositoires d'un medicament provoquant, en cas d'administration orale, des troubles gastro-intestinaux ou se decomposant sous l'effet de l'acide gastrique
MXPA99011474A (en) Polymer based pharmaceutical compositions for targeted delivery of biologically active agents
CN112587651B (zh) 一种布雷默浪丹口服药物组合物及其应用
Amir et al. ENHANCEMENT OF ORAL UPTAKE OF AMIKACIN USING COPOLYMERS
KR950009089B1 (ko) 약리학적 제제의 전달 시스템
MXPA99011581A (en) Targeted liposomal constructs for diagnostic and therapeutic uses
AU2002326564A1 (en) Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
JP2004315514A (ja) 経皮吸収製剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98807413.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/011474

Country of ref document: MX

Ref document number: 85912/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998937127

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2297025

Country of ref document: CA

Ref document number: 2297025

Country of ref document: CA

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998937127

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998937127

Country of ref document: EP